A phase I trial of bryostatin-1 in children with refractory solid tumors: A Pediatric Oncology Group Study

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2344-2348

  Weitman, Steven ^a,h   Langevin, Anne Marie ^a   Berkow, Roger L ^b   Thomas, Paul J ^a   Hurwitz, Craig A ^c   Kraft, Andrew S ^d   Dubowy, Ronald L ^e   Smith, Debra L ^f   Bernstein, Mark ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Maine Children's Cancer Program Portland   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h Operations Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BRYOSTATIN 1;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; FEVER; GENE EXPRESSION; HEADACHE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR PROMOTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTONES; MACROLIDES; MALE; NEOPLASMS; THROMBOCYTOPENIA;

EID: 0032882880     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pettit, G., Herald, C., Doubek, D., and Herald, D. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982.
2. Hornung, R., Pearson, J., Beckwith, M., and Longo, D. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
3. Schuchter, L., Esa, A., May, W., Laulis, M., Pettit, G., and Hess, A. Successful treatment of murine melanoma with bryostatin 1. Cancer Res., 51: 682-687, 1991.
4. Pettit, G., Day, J., Hartwell, J., and Wood, H. Antineoplastic components of marine animals. Nature (Lond.), 227: 962-963, 1970.
5. Mohammad, R., Al-Katib, A., Pettit, G., and Sensenbrener, L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
6. Jones, R., Sharkis, S., Miller, C., Rowinsky, E., Burke, P., and May, S. Bryostatin-1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood, 75: 1319-1323, 1990.
7. Jalava, A., Heikkila, J., Akerlind, G., Pettit, G., and Akerman, K. Effects of bryostatin 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Cancer Res., 50: 3422-3428, 1990.
8. Gescher, A. Towards selective pharmacological modulation of protein kinase C - opportunities for the development of novel antineoplastic agents. Br. J. Cancer, 66: 10-19, 1992.
9. Basu, A. The potential of protein kinase C as a target or anticancer treatment. Pharmacol. Ther., 59: 257-280, 1993.
10. Maki, A., Diwakaran, H., Redman, B., Al-Asfar, S., Pettit, G., Mohammad, R., and Al-Katib, A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs, 6: 392-397, 1995.
11. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
12. Kraft, A., Woodley, S., Pettit, G., Gao, F., Coll, J., and Wagner, F. Successful treatment of murine melanoma with bryostatins 5 and 8. Cancer Chemother. Pharmacol., 37: 271-278, 1998.
13. Philip, P., Rea, D., Thavasu, P., Carmichael, J., Stuart, N., Rockett, H., Talbot, D., Ganesan, T., Pettit, G., Balkwill, F., and Harris, A. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor a induction in vivo. J. Natl. Cancer Inst., 85: 1812-1818, 1993.
14. Prendiville, J., Crowther, D., Thatcher, N., Woll, P., Fox, B., McGown, A., Testa, N., Stern, P., McDermott, R., Potter, M., and Pettit, G. A Phase I study of intravenous bryostatin 1 inpatients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
15. Grant, S., Roberts, J., Poplin, E., Tombes, M., Kyle, B., Welch, D., Carr, M., and Bear, H. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res., 4: 611-618, 1998.
16. Jayson, G., Crowther, D., Prendiville, J., McGown, A., Scheid, C., Stern, P., Young, R., Brenchley, P., Chang, J., and Owens, S. A Phase I trial of bryostatin 1 inpatients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.
17. Varterasian, M., Mohammad, R., Eilender, D., Hulburd, K., Rodriguez, D., Pemberton, P., Pluda, J., Dan, M., Pettit, G., Chen, B., and Al-Katib, A. Phase I study of bryostatin 1 inpatients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol., 16: 56-62, 1998.
18. Day, S. In: D. Taylor (ed.), Paediatric Ophthalmology, Chapter P9: Photophobia. pp. 1034-1036. London: Blackwell Science, 1997.
19. Berkow, R., Schlabach, L., Dodson, R., Benjamin, W., Pettit, G., Rustagi, P., and Kraft, A. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res., 53: 2810-2815, 1993.
20. Basu, A., and Lazo, J. Sensitization of Hela cells to cis-diamminedichloroplatinum by bryostatin 1. Proc. Am. Assoc. Cancer Res., 33: A3036, 1992.
21. Mohammad, R., Diwakaran, H., Maki, A., Emara, M., Pettit, G., Redman, B., and Al-Katib, A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk. Res., 19: 667-673, 1995.
22. Grant, S., Jarvis, W., Swerdlow, P., Turner, A., Traylor, R., Wallace, H., Lin, P., Pettit, G., and Gewirtz, D. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res., 52: 6270-6278, 1992.
23. Katato, K., Mohammad, R., and Dugan, M. Sequential treatment of chronic lymphocytic leukemia (CLL) with bryostatin 1 and 2-chlorodeoxyadenosine: a preclinical study. Exp. Hematol., 24: A693, 1996.
24. Al-Katib, A., Smith, M., Kamanda, W., Pettit, G., Hamdan, M., Mohamed, A., Chelladurai, B., and Mohammad, R. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res., 4: 1305-1314, 1998.
25. Mohammad, R., Katato, K., Almatchy, V., Wall, N., Liu, K., Schultz, C., Mantsch, H., Varterasian, M., and Al-Katib, A. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine:preclinical studies. Clin. Cancer Res., 4: 445-453, 1998.
26. Chelliah, J., Freemerman, A., Wu Pong, S., Jarvis, W., and Grant, S. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc. Biochem. Pharmacol., 54: 563-573, 1997.
27. Kawasaki, H., Carrera, C., Piro, L., Saven, A., Kipps, T., and Carson, D. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood, 81: 597-601, 1993.